Atomo Diagnostics secures $630,000 HIV Self-Test order from NAPWHA
Atomo Diagnostics has secured another purchase order worth approximately $630,000 from the National Association of People with HIV Australia (NAPWHA) for supply of HIV Self-Tests. The Atomo Diagnostics HIV Self-Test Order supports the national free-to-user HIV Self-Testing program, which is funded by the Federal Government under new public HIV health policy. The company considers the revenue from this order to be material.
The order demonstrates continued demand from NAPWHA’s mail-out program, which has proven successful in increasing testing rates among high-risk cohorts who had not been testing sufficiently or, in many cases, not testing at all. The Federal Government has committed to continued funding of key HIV Self-Test programs, providing visibility for ongoing demand.
How HIV self-testing programs work in Australia
NAPWHA operates a national mail-out program that delivers free HIV self-tests directly to homes across Australia. The program targets high-risk populations who may avoid clinical testing settings due to privacy concerns or accessibility barriers.
The initiative is supported by Grindr, the world’s largest social networking app for the LGBTIQ+ community, which helps raise awareness about the availability of free at-home testing. Program expansion aims to increase availability of HIV self-tests and support growing awareness around discrete, convenient testing options.
At-home testing removes barriers associated with clinical visits, enabling individuals to test in private settings. This approach has successfully reached populations that were previously under-testing, addressing a critical gap in public health surveillance and early detection.
The role of public health partnerships in diagnostics revenue
Atomo functions as the product supplier within a broader ecosystem where NAPWHA manages program delivery, the Federal Government provides funding, and Grindr facilitates community awareness. This partnership model demonstrates how diagnostics companies can access stable revenue streams through government-backed health initiatives.
John Kelly, Atomo CEO
“We have developed a very good working relationship with NAPWHA and other partners here in Australia to ensure that discrete, convenient testing is available to those wishing to know their status. We are delighted to be in a position to provide additional Atomo tests to support this invaluable program.”
The repeat order nature of this relationship indicates established commercial momentum with a customer backed by Federal Government funding commitments. This model could potentially extend to other geographies or public health programs where governments prioritise accessible testing infrastructure.
What this order means for Atomo’s commercial momentum
The $630,000 order represents repeat business from an established customer, reducing customer acquisition costs and providing evidence of product satisfaction. The Federal Government’s commitment to continued funding of HIV self-test programs suggests potential for further orders, though no specific forward guidance has been provided.
Atomo’s broader commercial focus spans multiple diagnostic applications:
- Sexual health testing (including HIV self-tests)
- Infectious disease diagnostics (rapid point-of-care applications)
- Female health applications (rapid diagnostic devices)
The company supplies integrated rapid diagnostic test devices to global markets, with patented technology designed to simplify testing procedures and improve reliability across point-of-care and at-home settings. Government-backed programs provide stable demand independent of consumer marketing expenditure, supporting recurring revenue visibility.
Next steps and outlook
Program expansion and growing awareness around free at-home testing indicate potential for continued demand, supported by the Federal Government’s funding commitment. Atomo’s positioning as a supplier to public health initiatives provides exposure to government-backed procurement cycles.
The company has not provided specific forward guidance beyond this order. However, the repeat nature of NAPWHA orders and the government’s stated commitment to funding HIV self-test programs suggest ongoing commercial activity in this segment.
Atomo maintains supply agreements across international markets for testing applications targeting infectious diseases and female health, positioning the company within multiple diagnostic categories beyond the Australian HIV self-testing program.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to stay ahead on market-moving announcements the moment they break.